Our Beliefs
At MKM Biotech, we believe that the current pharmaceutical market is ideal for innovations based on biodiversity.
The sector faces a landscape filled with opportunities, as the looming expiration of blockbuster drug patents draws near.
By 2030, over $200 billion in annual revenue will be at risk, pressuring the industry to seek new therapeutic solutions to fill the gaps left by these losses.
In this context, Brazil stands out as the perfect place for the discovery of new medicines, thanks to its unparalleled biodiversity.
Our country holds 21% of all known plant species and a vast wealth of yet unexplored natural resources.
This creates a fertile environment for the development of new treatments derived from natural products, including plants, animals, and microorganisms, which have a significantly higher success rate when compared to synthetic compounds.
At MKM Biotech, we believe we are uniquely and precisely positioned to capitalize on this moment.
With our focus on investing in scientific research and developing them until M&A readiness (build-to-buy), we are ready to meet the global demand for new therapies, driving innovations that can transform the future of healthcare.